MaaT Pharma SA

DB:4RD Stock Report

Market Cap: €111.9m

MaaT Pharma Management

Management criteria checks 1/4

MaaT Pharma's CEO is Herve Affagard, appointed in Dec 2014, has a tenure of 10.08 years. total yearly compensation is €1.37M, comprised of 21.9% salary and 78.1% bonuses, including company stock and options. directly owns 1.68% of the company’s shares, worth €1.88M. The average tenure of the management team and the board of directors is 1.2 years and 4.7 years respectively.

Key information

Herve Affagard

Chief executive officer

€1.4m

Total compensation

CEO salary percentage21.9%
CEO tenure10.1yrs
CEO ownership1.7%
Management average tenure1.2yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Herve Affagard's remuneration changed compared to MaaT Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€24m

Mar 31 2024n/an/a

-€22m

Dec 31 2023€1m€300k

-€20m

Sep 30 2023n/an/a

-€17m

Jun 30 2023n/an/a

-€15m

Mar 31 2023n/an/a

-€14m

Dec 31 2022€734k€292k

-€14m

Sep 30 2022n/an/a

-€13m

Jun 30 2022n/an/a

-€12m

Mar 31 2022n/an/a

-€11m

Dec 31 2021€279k€198k

-€9m

Sep 30 2021n/an/a

-€8m

Jun 30 2021n/an/a

-€7m

Mar 31 2021n/an/a

-€6m

Dec 31 2020€831k€233k

-€5m

Compensation vs Market: Herve's total compensation ($USD1.40M) is above average for companies of similar size in the German market ($USD459.99K).

Compensation vs Earnings: Herve's compensation has increased whilst the company is unprofitable.

CEO

Herve Affagard (49 yo)

10.1yrs

Tenure

€1,368,888

Compensation

Mr. Herve Affagard is Co-Founder at MaaT Pharma SA and is its CEO since December 3, 2014. He is Director at MaaT Pharma SA since 2014.

Leadership Team

NamePositionTenureCompensationOwnership
Herve Affagard
CEO, Co-Founder & Director10.1yrs€1.37m1.68%
€ 1.9m
Joel Dore
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Pierre Rimbaud
Co-Founderno datano datano data
Eric Soyer
Chief Financial Officerless than a yearno datano data
Carole Schwintner
Technology Director & Chief Technology Officerno datano datano data
Nathalie Corvaia
Chief Scientific Officer2.3yrsno datano data
Guilhaume Debroas
Head of Investor Relations1.6yrsno datano data
Sian Crouzet
Chief of Staffless than a yearno datano data
Emilie Plantamura
Head of Clinical Development1.6yrsno datano data
Jonathan Chriqui
Chief Business Officerless than a yearno datano data
Gianfranco Pittari
Chief Medical Officerless than a yearno datano data

1.2yrs

Average Tenure

Experienced Management: 4RD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Herve Affagard
CEO, Co-Founder & Director11yrs€1.37m1.68%
€ 1.9m
Joel Dore
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Claude Bertrand
Independent Non-Executive Director4.5yrs€35.00kno data
Karim Dabbagh
Independent Chairman1.6yrs€29.25k0.014%
€ 15.8k
Jean Volatier
Independent Non Executive Director4yrs€45.00kno data
Robert Jenq
Member of Scientific Advisory Board4.7yrsno datano data
Ernst Holler
Chair of Scientific Advisory Board4.7yrsno datano data
Florent Malard
Member of Scientific Advisory Board4.7yrsno datano data
Robert Zeiser
Member of Scientific Advisory Board4.7yrsno datano data
Jean-Marie Lefevre
Non-Executive Director9yrsno datano data
Dorothee Burkel
Independent Non Executive Director4yrs€37.00kno data
Nadia Kamal
Independent Director1.6yrs€24.25kno data

4.7yrs

Average Tenure

59yo

Average Age

Experienced Board: 4RD's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/13 02:54
End of Day Share Price 2025/01/13 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MaaT Pharma SA is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stephanie LefebvreGilbert Dupont
Thomas VrankenKBC Securities NV
Jacob MekhaelKBC Securities NV